Uli Wellner

Associate Professor of Surgery
Pancreatic Surgery and Research, University of Lübeck, Germany

[Anirban Maitra @Aiims1742]

Data from Tango slide deck of PRMT5inh plus KRASinh (Daraxonrasib, left and Zoldonrasib, right) in 2nd/3rd line #PancreaticCancer
https://t.co/4WANawY4iY

In this recent study (Boston Gene), ~20% of pancreatic cancers have KRAS mut plus MTAP co-deletion.
https://t.co/XHwHtlpjYy

[Marc Besselink @MarcBesselink]

🔥 The #PORSCH trial 🇳🇱 algorithm following #Pancreatic Surgery @DPCG_official also improves overall survival!

[Giovanni Marchegiani @Gio_Marchegiani]

Harms 😈 and benefits 👼 of Pancreatic Cyst Surveillance Guidelines - 3 guidelines compared

🌎 Microsimulation analysis in @AGA_Gastro on 8.6 million pts

👉 Overall Harm-to-benefit ratio disappointing 👈

✋ STOP surveillance in stable cysts not harm

https://t.co/v2l6FEm80q

[Anirban Maitra @Aiims1742]

Retrospective single center study from @GustaveRoussy confirms prior findings on the favorable prognosis of lung only metastatic #PancreaticCancer & highlights some of the molecular differences with other metastatic sites.
https://t.co/PXQuTSvdLh

[Giovanni Marchegiani @Gio_Marchegiani]

🔵 Oligometastatic pancreas cancer: what's the best treatment !? 🔵

🛰️ The RCT SONAR multicenter study is up and running

🗳️ Pts randomised 1:1 after chemo selection into surgery vs. observation / continued chemo

https://t.co/7nhTRtTy2I

[Arndt Vogel @ArndtVogel]

Precision medicine strategy in pancreatic ductal adenocarcinoma
@ESMO_Open
https://t.co/8giC5QAJen
🔎342 pts
👉20% of pts with 🎯alterations, including olaparib (BRCA2), trastuzumab (HER2), and KRAS G12C inhibitors
👉MMT with significant survival benefit
@myESMO

[Giovanni Marchegiani @Gio_Marchegiani]

🌈 The good news we were all waiting for...

💪 Recurrence patterns and survival of pancreas cancer in the neoadjuvant era: significant improvements

🫂 2 decades / 700 pts 🇺🇸
📈 Overall survival from 30 to 50 months
💉 Multimodal regimen revolution!

https://t.co/UdbyPmlpRH

[Marc Besselink @MarcBesselink]

Is minimally invasive (robot) #Whipple surgery just as safe as open surgery?

Today: #DIPLOMA2 RCT in @NEJMEvidence
➡️ https://t.co/hxoIzVHpfB

288 patients, 14 expert centers, 6 countries 🇳🇱🇮🇹🇩🇪🇧🇪🇪🇸🇸🇪): MIS equally safe as open in experienced centers. With faster recovery, fewer wound complications, less pancreatic fistula, and a shorter hospital stay.

@nine_degraaf @AnoukEmmen @Abuhilal9Abu @e_mips @EAHPBA

[Anirban Maitra @Aiims1742]

Exercise as anti-cancer medicine
(“Exercizumab”)
@Cancer_Cell
https://t.co/51bb4qGQfY
@JCO_ASCO
https://t.co/tBcD44WuML

[Giovanni Marchegiani @Gio_Marchegiani]

The value 💍 of active surveillance of IPMN 🍇 goes beyond cysts evolution…

🇯🇵 3.6k ipmn / 63 concomitant PDAC detected!

☢️ Earlier stage diagnosed 🪡 57% R0 resected

💪 Concomitant PDAC found during IPMN surveillance benefit from early diagnosis

https://t.co/x7V3ezvWy0

[Steven D Wexner MD, PhD @SWexner]

Clinical implications of postoperative hyperamylasemia and postpancreatectomy acute pancreatitis after pancreatectomy: A systematic review and meta-analysis https://t.co/btDwh7xnmC thank you @Gio_Marchegiani @UniPadova for another excellent open access @SurgJournal publication

[Marc Besselink @MarcBesselink]

Do you offer #video #consultations to your patients when explaining and consenting to major abdominal (eg #pancreas #liver #esophageal surgery?

Today in @LancetDigitalH our multicenter non-inferiority randomised #VIDEOGO trial, including 112 surgical patients. First RCT done in this preop setting.

📎 Patient satisfaction score video consultation non-inferior

📎 Information recall score after video consultation non-inferior

📎 Surgeon satisfaction score video consultation non-inferior

📎 Efficacy outcomes were in favor of video consultations. Per video consultation patients:
🕜 saved 2 hours due to less preperation and travel time
💰saved €18,- due to no travel and parking costs
🌳 reduced their carbon footprint by 99%

Technical issues reported in only 7% and solved during the same consultation!

https://t.co/ZVwqY4B72z

[Ville Sallinen @villesallinen]

New 🇫🇮🇳🇴RCT out @JAMASurgery 🔥 Results from antibiotics layer of the PERFECT trial:
Antibiotics or no while awaiting for appendectomy for presumed uncompl appendicitis

1797 patients
Perforations: 8.3% vs 8.9%
Surg site infections: 1.6% vs 3.2% (p=0.03)

https://t.co/BmfqTHjaOG

[Syed A. Ahmad @SyedAAhmad5]

Carbohydrate antigen 19-9 (CA19-9) response after induction FOLFIRINOX for locally advanced pancreatic cancer identifies patients who may benefit from surgical exploration: multicentre, observational cohort study ⁦@BJSurgery⁩ https://t.co/UxBH9YcjUs

[Annals of Surgery @AnnalsofSurgery]

The PAncreatic surgery Composite Endpoint PACE – Development and validation of a clinically relevant endpoint requiring lower sample sizes.
https://t.co/IjJ92zIuey

[Annals of Surgery @AnnalsofSurgery]

Advancing pig kidney xenotransplantation: Improved gene editing and immunosuppression suggest it's time for pilot clinical trials to tackle the organ shortage. Ethical frameworks and careful patient selection are essential for success.
https://t.co/DhrJ7E7XhL

[Annals of Surgery @AnnalsofSurgery]

Robotic pancreatoduodenectomy (RPD) outperforms laparoscopic (LPD) in operative time, conversion rate, & blood transfusion, with similar oncologic outcomes. In experienced hands, both are safe.
https://t.co/mbpmRTpdx3

[Marc Besselink @MarcBesselink]

How do costs of robot 🤖 vs open pancreatoduodenectomy compare? Will costs become similar over time?

588 pts A’dam 🇳🇱 (214 RPD, 374 OPD)

⛔️Overall, costs €4,804 ⬆️ for RPD (€27,307 vs. €22,503, P=0.010)
✅Outcomes RPD improved in the 2nd half experience (n=107): hospital stay 3 dys⬇️, pancreatic fistula 16%⬇️, DGE 18%⬇️, operative time 63’⬇️ etc
✅ Hence, costs RPD⬇️: in the 2nd half €11,058 less (!!) vs 1st half RPD
🔑 Costs in the 2nd half RPD vs OPD comparable (€21,778 vs. €21,013) while RPD associated with shorter stay, less DGE, less wound infection, less blood loss
✅DIPLOMA-2 coming up…..

▶️https://t.co/F1CQtjas3x

#pancreaticcancer #surgery #Whipple

[Giovanni Marchegiani @Gio_Marchegiani]

🟢 Adjuvant chemo after resection of PDAC following preop FOLFIRINOX

700 patients 💉 2-11 FOLFIRINOX 🔪 surgery localized PDAC 💉 adjuvant chemo

👍 Adjuvant multiagent chemo improved survival

❌ Single agent did not

🔑 RCT needed !!!

https://t.co/uvhKm9garF

[Annals of Surgical Oncology @AnnSurgOncol]

January Issue: Neoadjuvant Treatment with Changes in #ChemotherapyRegimens According to Carbohydrate Antigen 19-9 Level for Resectable/Borderline Resectable #PancreaticDuctalAdenocarcinoma

https://t.co/xH7F9wVOHD

@DavidCabaMD
@SyedAAhmad5